Hutch News

Hutch News

Stories tagged 'cancer immunotherapy trials network'

Meet Global Oncology's deputy program head

Key early experiences shaped Dr. Thomas Uldrick's path toward HIV-associated cancers, global health

Feb. 22, 2018 | By Mary Engel / Fred Hutch News Service

Dr. Thomas Uldrick brings expertise in HIV-related cancers and experience in — and a passion for — developing clinical trials to his new position at Fred Hutch Global Oncology.

View story >


For cancer patients with HIV, immunotherapy appears safe

Checkpoint inhibitor study suggests new treatment options for patients long excluded from cancer immunotherapy clinical trials

Nov. 7, 2017 | By Mary Engel / Fred Hutch News Service

Checkpoint inhibitor study suggests new treatment options for patients long excluded from cancer immunotherapy clinical trials.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Feb. 2, 2017

Novel gene therapy for sickle cell disease and related disorders on the horizon; immunotherapy trial in rare skin cancer named one of 2016’s major advances in clinical cancer research and care; Dr. Cara McDermott receives AcademyHealth new investigator award; and study documents sperm changes years after chemotherapy.

View story >


How research and industry partnerships can advance cancer care

Fred Hutch, Merck co-host inaugural ‘Oncology Summit’ to capture non-profit and for-profit outlooks on cancer care

Sept. 27, 2016 | By Rachel Tompa / Fred Hutch News Service

Inaugural 'Oncology Summit,' co-hosted by Fred Hutch and Merck, allowed investors, key players in life sciences to collaborate and share scientific stories.

View story >


'Finally showing hope'

Immunotherapy trial results transforming care for rare skin cancer

April 19, 2016 | By Susan Keown / Fred Hutch News Service

With few remaining options for treating his aggressive Merkel cell carcinoma, Stan Collender joined a clinical trial of the immune-modulating drug pembrolizumab. The trial's results are giving new hope to people with this rare cancer.

View story >


Scratching the surface of a rare skin cancer

Immune-boosting therapy shows promise for advanced Merkel cell carcinoma

Oct. 6, 2015 | By Dr. Rachel Tompa / Fred Hutch News Service

Skin cancer researcher Dr. Paul Nghiem is leading a clinical trial testing the immunotherapy drug pembrolizumab for patients with advanced Merkel cell carcinoma, a rare and aggressive skin cancer. Early results from the trial are showing great promise for these patients.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.